Russell L. Chin, MD, is Medical Director at Neurvati Neurosciences and GRIN Therapeutics. Prior to joining Neurvati, Dr. Chin was Medical Director in the Neuromuscular Development Unit at Biogen, where his research focus was on spinal muscular atrophy. He served as project lead and clinical development lead on a collaboration to study the safety and efficacy of an implanted port-catheter system for intrathecal delivery of SPINRAZA (nusinersen). He has also served as medical director for several clinical trials of SPINRAZA.
Dr. Chin completed neurology residency training at New York Presbyterian Hospital and was chief resident at Weill Cornell Medical College, where he completed fellowships in clinical neurophysiology and peripheral neuropathy and was associate professor in the neurology faculty. He worked at the Peripheral Neuropathy Center and has authored publications on various neuropathies including chronic inflammatory demyelinating polyneuropathy (CIDP), neuropathies associated with celiac disease, and small fiber neuropathy (SFN). He also served as director of the EMG Laboratory.